Oral Composition
Patent Information
- Application Number
- JP2021091916
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-05-31
- Publication Date
- 2025-10-17
- Estimated Expiration
- 2041-05-31
AI Technical Summary
Conventional oral compositions are inadequate in suppressing the expression of SREBF1 or promoting the expression of PPARα, HO-1, or NOS3, failing to effectively manage cholesterol and triglyceride levels, improve brain function, alleviate depressive states, enhance stress resistance, improve blood flow, or address erectile dysfunction.
An oral composition containing gallic acid and a combination of pomegranate, shilajit, hibiscus, mastic, and goldenrod or mango, with specific mass percentages and ratios, to inhibit or promote the expression of these proteins, thereby addressing the mentioned health issues.
The composition effectively suppresses or promotes the expression of SREBF1, PPARα, HO-1, and NOS3, leading to improved cholesterol and triglyceride management, enhanced brain function, reduced depressive states, increased stress resistance, improved blood flow, and alleviated erectile dysfunction.
Smart Images

Figure 0007755840000001 
Figure 0007755840000002 
Figure 0007755840000003
Abstract
Citation Information
Patent Citations
Medical health food
JP2002238496A
Nutrition supplement of plant nutrient
JP2004035550A
Medicine for treating or preventing angiofibrosis
JP2007126480A
Mango extract
JP2009215235A
A composition effective in preventing or slowing the progression of prostate cancer.
JP2011529465A